R., Lingvay, I., Ludemann, J., Andreassen, C., Navarria, A., & Viljoen, A
How do the potential benefits of GLP-1 agonists in reducing risks of heart and kidney disease compare with the risks of side effects like hypoglycemia or gallbladder disorders, and how should a clinician balance these considerations
Vague or absent mechanism explanations suggest speculation rather than established fact
Regular reassessment with healthcare providers helps determine the ongoing need for treatment, with consideration of factors such as treatment response, side effects, and changes in health status or treatment goals
Published research, receptor overlap risks, and what clinical data shows
Take doses with food for better tolerance